University of California

Wisconsin Alumni Research Foundation

Other

Tony L Yaksh

Sandra Reading Chaplan

Marc Marino

Flemming Winther Bach

Eric Arthur Johnson

William Howard Tepp

Sabine Pellett

Qinghao Xu

Yury Miller

Alan L Maycock

Edward A Dennis

George Kokotos

Violetta Constantinou-Kokotou

George T Ozaki

Harlan F Hill

Karin Killermann Lucas

Camilla Svensson

David A Six

Shelle Malkmus

In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia. In alternative embodiments, provided are methods comprising administering formulations and pharmaceutical compositions comprising an APOA1BP polypeptide or protein that is a human or a mammalian APOA1BP, or an AIBP1 or an AIBP2, or a recombinant, peptidomimetic or a synthetic APOA1BP, or a bioisostere of an ApoA-I Binding Protein to treat, ameliorate prevent, reverse, decrease the severity of a neuropathic pain, a TLR4-mediated allodynia and/or a hyperalgesia.

Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine

A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.

Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

The invention provides a method for automated assessment of pruritus comprising detecting movement of a band located on a limb of a subject animal so as to obtain a signal associated with the detection movement, processing the signal associated with the detected movement through an algorithm configured to establish a scratch movement trigger, and translating the processed signal into scratch counts.

Automated scratch detection system and signal processing algorithm for the study of pruritus in animals

Specific, highly potent 2-oxo-amide based inhibitors of phospholipase A(PLA) activity are provided. A role for PLAactivity in spinally mediated inflammatory processes is established, and a method for treating hyperalgesia and other inflammatory conditions associated with PLAactivity is provided.

Compositions and methods for inhibition of phospholipase A2 mediated inflammation

An apparatus and method for measuring spatial displacement of an animal's paw injected with irritant. This apparatus comprises an electromagnetic detecting assembly having () a transmitting oscillator for generating electrical current () an electromagnetic transmitter coil coupled to the oscillator for generating an electromagnetic field () an electromagnetic receiving coil placed in axial plane directly below the transmitter coil () a first, receiving amplifier connected to the receiving coil () an amplitude detector connected to the receiving amplifier () a second amplifier connected to the amplitude detector () a metal object attached to the animal's paw () and a cylindrical observation chamber of a diameter not greater than the diameter of the generated magnetic field.

Apparatus and method for detecting flinch response to nociceptive agents

Compositions and methods using the compositions for treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit central nervous system side effects.

Peripherally active anti-hyperalgesic opiates

Compositions and methods using the compositions for treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit substantial central nervous system effects. The anti-diarrheal compound 4-(p-chlorophenyl)-4-hydroxy-N-N-dimethyl-&agr;,&agr;-diphenyl-1-piperidinebutyramide hydrochloride is preferred for use in the compositions and methods.

The invention relates to methods of producing analgesia, particularly in the treatment-of-acute and persistent pain and neuropathic pain. The compound 2(ethylamino)-N-(3-hydroxy-2,6-dimethylphenyl) acetamide, or 3-hydroxymonoethylglycinexylidide (3-hydroxy MEGX), is shown to provide analgesia in settings of acute, persistent and neuropathic pain.

Method of producing analgesia

Methods for treatment of peripheral hyperalgesia are provided, comprising administering compositions containing an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit central nervous system side effects. The anti-diarrheal compound 4-(.rho.-chlorophenyl)-4-hydroxy-N-N-dimethyl-.alpha.,.alpha.-diphenyl-1-p iperidinebutyramide hydrochloride is preferred for use in the methods.

Compositions and methods using the compositions for treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit substantial central nervous system effects. The anti-diarrheal compound 4-(p-chlorophenyl)-4-hydroxy-N-N-dimethyl-.alpha.,.alpha.-diphenyl-1-piper idinebutyramide hydrochloride is preferred for use in the compositions and methods.

Compositions and methods for alleviating pain (in particular, neuropathic pain) in a mammalian patient, wherein an effective amount of a physiologically-acceptable salt of a compound of the general formula ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 is independently selected from the group consisting of hydrogen, hydroxyl, acyl, alkoxyl, alkyl, aryl, alkylaryl, arylalkyl, hydroxyalkyl, hydroxyaryl, alkoxyalkyl, alkoxyaryl and NR.sup.8 R.sup.9, in which each of R.sup.8 and R.sup.9 is independently selected from the group consisting of hydrogen, alkyl, aryl, acyl, alkylaryl, arylalkyl, hydroxyalkyl, hydroxyaryl, alkoxyalkyl and alkoxyaryl, with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 is hydroxyl;

Compositions and methods for treating pain

Methods using compositions for the treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit central nervous system side effects. The anti-diarrheal compound 4-(p-chlorophenyl)-4-hydroxy-N-N-dimethyl-.alpha.,.alpha.-diphenyl-1-piper idinebutyramide hydrochloride is preferred for use in the compositions of the claimed methods.

Growing community of inventors

San Diego, CA, United States of America

Tony L Yaksh